Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials

被引:26
|
作者
Privitera, Michael [1 ]
Bhathal, Hari [2 ]
Wong, Matthew [3 ]
Cross, J. Helen [4 ]
Wirrell, Elaine [5 ]
Marsh, Eric D. [6 ]
Mazurkiewicz-Beldzinska, Maria [7 ]
Villanueva, Vicente [8 ]
Checketts, Daniel [9 ]
Knappertz, Volker [10 ]
VanLandingham, Kevan [10 ]
机构
[1] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA
[2] Neuroctr Barcelona, Teknon Med Ctr, Barcelona, Spain
[3] Wake Forest Baptist Med Ctr, Winston Salem, NC USA
[4] UCL, Great Ormond St Inst Child Hlth, Natl Inst Hlth Res, Biomed Res Ctr, London, England
[5] Mayo Clin, Rochester, MN USA
[6] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[7] Med Univ Gdansk, Gdansk, Poland
[8] Univ & Polytech Hosp La Fe, Valencia, Spain
[9] GW Res Ltd, Cambridge, England
[10] Greenwich Biosci Inc, Carlsbad, CA USA
关键词
antiepileptic drug; antiseizure medication; childhood onset epilepsy; drop seizures; treatment‐ resistant epilepsy;
D O I
10.1111/epi.16878
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective To estimate time to onset of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]), we conducted post hoc analyses of data from two randomized, placebo-controlled, Phase 3 trials, GWPCARE3 (NCT02224560) and GWPCARE4 (NCT02224690), of patients with Lennox-Gastaut syndrome. Methods Patients received plant-derived pharmaceutical formulation of highly purified CBD (Epidiolex, 100 mg/ml oral solution) at 10 mg/kg/day (CBD10; GWPCARE3) or 20 mg/kg/day (CBD20; both trials) or placebo for 14 weeks. Treatment started at 2.5 mg/kg/day for all groups and reached 10 mg/kg/day on Day 7 and 20 mg/kg/day (CBD20 and matching placebo only) on Day 11. Percentage change from baseline in drop seizure frequency was calculated by cumulative day (i.e., including all previous days). Time to onset and resolution of AEs were evaluated. Results Overall, 235 patients received CBD (CBD10 [GWPCARE3 only], n = 67; CBD20 [pooled GWPCARE3&4], n = 168) and 161 received placebo. Mean (range) age was 15.3 years (2.6-48.0). Patients had previously discontinued a median (range) of six (0-28) antiepileptic drugs (AEDs) and were currently taking a median of three (0-5) AEDs. Differences in drop seizure reduction between placebo and CBD emerged during the titration period and became nominally significant by Day 6 (p = .008) for pooled CBD treatment groups. Separation between placebo and CBD in >= 50% responder rate emerged by Day 6. Onset of the first reported AE occurred during the titration period in 45% of patients (CBD10, 46%; CBD20, 52%; placebo, 38%). In patients with AEs, resolution occurred within 4 weeks of onset in 53% of placebo and 39% of CBD patients and by end of study in 63% of placebo and 61% of CBD patients. Significance Treatment effect (efficacy and AEs) of CBD may occur within 1 week of starting treatment. Although AEs lasted longer for CBD than placebo, most resolved within the 14-week period.
引用
收藏
页码:1130 / 1140
页数:11
相关论文
共 50 条
  • [31] Treatment with Cannabidiol (CBD) Significantly Reduces Drop and Total Seizure Frequency in Lennox-Gastaut Syndrome (LGS): Results of a Multicenter, Randomized, Double-blind, Placebo Controlled Trial (GWPCARE4)
    Joshi, C.
    Thiele, E.
    Marsh, E.
    French, J.
    ANNALS OF NEUROLOGY, 2017, 82 : S293 - S293
  • [32] Nonseizure outcomes with cannabidiol (CBD) in pediatric versus adult patients with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS): Subgroup analysis of become, a caregiver survey
    Saurer, Timothy B.
    Dixon-Salazar, Tracy
    Berg, Anne T.
    Meskis, Mary Anne
    Danese, Sherry R.
    Le, Ngoc Minh D.
    Perry, M. Scott
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [33] Seizure Outcomes With Cannabidiol (CBD) in Pediatric Versus Adult Patients With Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS): Subgroup Analysis of BECOME, a Caregiver Survey
    Saurer, T.
    Berg, A.
    Dixon-Salazar, T.
    Meskis, M.
    Danese, S.
    Le, N.
    Perry, M.
    ANNALS OF NEUROLOGY, 2023, 94 : S54 - S54
  • [34] Nonseizure Outcomes With Cannabidiol (CBD) in Pediatric Versus Adult Patients With Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS): Subgroup Analysis of BECOME, a Caregiver Survey
    Dixon-Salazar, Tracy
    Berg, Anne T.
    Meskis, Mary Anne
    Danese, Sherry R.
    Saurer, Timothy B.
    Le, Ngoc Minh D.
    Perry, M. Scott
    NEUROLOGY, 2023, 100 (17)
  • [35] Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis
    Lattanzi, Simona
    Brigo, Francesco
    Cagnetti, Claudia
    Trinka, Eugen
    Silvestrini, Mauro
    CNS DRUGS, 2018, 32 (10) : 905 - 916
  • [36] Seizure outcomes with cannabidiol (CBD) in pediatric versus adult patients with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS): Subgroup analysis of become, a caregiver survey
    Saurer, Timothy B.
    Dixon-Salazar, Tracy
    Berg, Anne T.
    Meskis, Mary Anne
    Danese, Sherry R.
    Le, Ngoc Minh D.
    Perry, M. Scott
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [37] Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome
    Clements, Karen M.
    Skornicki, Michelle
    O'Sullivan, Amy K.
    EPILEPSY & BEHAVIOR, 2013, 29 (01) : 184 - 189
  • [38] Nonseizure Outcomes With Cannabidiol (CBD) in Pediatric Versus Adult Patients With Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS): Subgroup Analysis of BECOME, a Caregiver Survey
    Dixon-Salazar, T.
    Berg, A.
    Meskis, M.
    Danese, S.
    Saurer, T.
    Le, N.
    Perry, M.
    ANNALS OF NEUROLOGY, 2023, 94 : S54 - S55
  • [39] Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome
    Lattanzi, Simona
    Trinka, Eugen
    Striano, Pasquale
    Rocchi, Chiara
    Salvemini, Sergio
    Silvestrini, Mauro
    Brigo, Francesco
    CNS DRUGS, 2021, 35 (03) : 265 - 281
  • [40] COST-EFFECTIVENESS ANALYSIS OF ANTIEPILEPTIC DRUGS IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME
    Clements, K. M.
    Skornicki, M.
    O'Sullivan, A. K.
    VALUE IN HEALTH, 2012, 15 (04) : A144 - A144